The next domestically produced blockbuster that straddles two major diseases

Small molecule drugs have been around for a long time. Taking prostate cancer and breast cancer, which are the most common cancers in men and women in the US, respectively, the HR+/HER2-type first-line treatment drug “Duba Jianghu”, which accounts for nearly 70% of breast cancer, the three similar drugs have created a 10 billion dollar market, and the market size is growing steadily; this is even more true for prostate cancer. AR antagonists and CYP17 inhibitors for antiandrogen treatment have firmly grasped the first-line treatment market, spawning major bombs such as enzalutamide and alonbite. Today, whether it's a CDK4/6 inhibitor or an AR antagonist

Zhitong FinanceMay 30 21:15 ET

Laekna Enlists First Patient for Phase 3 Trial for Breast Cancer Treatment in China; Shares Rise 4%

Laekna (HKG:2105) enrolled the first patient for its China phase 3 clinical trial for the LAE002 combination with fulvestrant for certain forms of locally advanced or metastatic breast cancer, accordi

MT NewswiresMay 29 22:06 ET

Laikai Pharmaceutical-B (02105.HK): LAE 002 (AFURESERTIB) combined with fluvizil completed the first patient enrollment in a phase III clinical trial for HR+/HER2- locally advanced or metastatic breast cancer patients

Gelonghui, May 30丨Laikai Pharmaceutical-B (02105.HK) announced that LAE 002 (afuresertib, an oral AKT inhibitor) combined with fluvirizin (“combination therapy”) against PIK3CA/AKT1/PTEN-altered HR+/HER2-locally advanced or metastatic breast cancer (“LA/m BC”) in China has initiated patient recruitment and completed the first patient enrollment (“Phase III AFFIRM- Clinical Trial”) 205”). The III phase is approaching

Gelonghui FinanceMay 29 20:04 ET

US FDA Gives Green Light to Laekna's Phase 3 Trial for Prostate Cancer Drug; Shares Rise 8%

The US Food and Drug Administration approved Laekna's (HKG:2105) phase 3 clinical trial for the combination of its LAE002 and LAE001 drugs for metastatic castration-resistant prostate cancer, accordin

MT NewswiresMay 22 22:06 ET

Lai Kai Pharmaceutical-B (02105.HK): US FDA approves LAE 002 (AFURESERTIB) plus LAE 001 combination therapy phase III clinical trial plan for prostate cancer

On May 23, Ge Longhui Pharmaceutical-B (02105.HK) announced that the Group has obtained approval from the US Food and Drug Administration (“US FDA”) for LAE 002 (afuresertib, an AKT inhibitor) combined with LAE 001 (CYP17A1/CYP11B2 dual inhibitor) (“LAE201”) for patients with metastatic castration-resistant prostate cancer (mCRPC) after standard treatment. The group launched in the US in June 2021 and Korea in September 2022

Gelonghui FinanceMay 22 20:20 ET

Laikai Pharmaceutical-B plans to adopt a share award plan

Laikai Pharmaceutical-B (02105) issued an announcement. The board of directors of the company has resolved to approve the recommendation to adopt a share award plan, subject to shareholders' approval at the annual shareholders' meeting. According to the announcement, the purpose of the share award program is to attract and retain participants who have contributed significantly to the long-term growth and success of the Group, recognize and reward their past contributions to the Group, provide participants with an opportunity to obtain the company's exclusive rights and encourage participants to make further contributions to the company, and strive to enhance the value of the company and its shares in order to meet the overall interests of the company and its shareholders.

新浪港股May 21 19:26 ET